Sector News

J&J expands COVID-19 vaccine pact with Catalent for finishing work at Italian facility

July 7, 2020
Life sciences

Johnson & Johnson has been on a manufacturing deal spree as it nears human trials for its COVID-19 vaccine hopeful. On the same day it inked a $480 order from a Maryland CDMO, J&J announced it would expand its pact with another manufacturer to scale up production as fast as possible.

J&J has expanded its COVID-19 vaccine manufacturing pact with New Jersey-based Catalent to include work at the CDMO’s Anagni, Italy facility, a J&J spokesman said Monday.

New Jersey-based J&J initially tapped Catalent in April to reserve fill-finish capacity for its COVID-19 shot at its Bloomington, Indiana plant. As part of that deal, Catalent agreed to hire an additional 300 workers at the plant starting this month, with the goal of reaching 24/7 manufacturing schedules by January.

In an email, J&J didn’t specify what work Catalent would perform at the Anagni site, but the CDMO previously signed a deal with British drugmaker AstraZeneca to perform fill-finish and packaging duties for the University of Oxford’s adenovirus-based COVID-19 vaccine, AZD1222.

“The latest agreement with Catalent Pharma Solutions in Italy is a continuation of our partnership and represents progress in our overall efforts,” the drugmaker said.

J&J didn’t disclose the financial terms of the deal. A Catalent spokesman could not be reached for comment by press time.

During a visit to the Anagni site Monday, Italian Health minister Roberto Speranz indicated J&J’s vaccine would be completed at the 305,000-square-foot site, Reuters reported.

In mid-June, Catalent and AstraZeneca reached a deal for finish-fill duties at the Anagni site, with Catalent pledging to produce “hundreds of millions of doses” beginning in August 2020 and potentially running through March 2022 if the vaccine receives full regulatory approval.

On Monday, J&J signed a five-year supply deal with Maryland-based Emergent BioSolutions to produce even more of its COVID-19 shot. The first two years of that deal are valued at $480 million, with doses provided as needed in the final three years.

As the initial step in what was pitched as the “first in a series” of manufacturing deals in March, J&J tapped Emergent to help boost production of its shot, which the company hopes to move into phase 1/2 trials later this month.

As part of the deal, J&J pledged to expand its own capacity for producing the vaccine with Emergent sharing its “molecule-to-market” manufacturing know-how. Emergent also reserved capacity at its Bayview Baltimore facility to support a potential commercial rollout of J&J’s shot beginning as early as 2021, should it nab an approval.

By: Kyle Blankenship

Source: Fierce Pharma

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.